The pharmacokinetics of midazolam and 1-OH-midazolam during oral premedication in paediatric patients

Alicja Bartkowska-Śniatkowska; Pawel Wiczling; Magdalena Juzwa-Sobieraj; Ewelina Kałużna; Bogna Świątek-Kościelna; Agnieszka Bienert; Agnieszka Borsuk; Artur Tezyk; Jowita Rosada-Kurasinska; Danuta Januszkiewicz-Lewandowska

doi:10.20883/jms.2016.112

Authors

Alicja Bartkowska-Śniatkowska Poznan University of Medical Sciences, Department of Paediatric Anaesthesiology and Intensive Therapy
Pawel Wiczling Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk
Magdalena Juzwa-Sobieraj Department of Pediatric Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences,
Ewelina Kałużna Department of Molecular Pathology, Institute of Human Genetics of the Polish Academy of Sciences, Poznan
Bogna Świątek-Kościelna Department of Molecular Pathology, Institute of Human Genetics of the Polish Academy of Sciences, Poznan
Agnieszka Bienert Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences,
Agnieszka Borsuk Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk
Artur Tezyk Department of Forensic Medicine, Poznan University of Medical Sciences
Jowita Rosada-Kurasinska Department of Pediatric Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences
Danuta Januszkiewicz-Lewandowska Department of Molecular Pathology, Institute of Human Genetics of the Polish Academy of Sciences, Poznan Department of Oncology, Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences

DOI:

https://doi.org/10.20883/jms.2016.112

Keywords:

midazolam, midazolam pharmacokinetic model, 1-OH-midazolam

Abstract

Objective. Development of midazolam (MDZ) pharmacokinetic model is pivotal for predicting drug response and determining appropriate dosing in patients who undergo surgical procedures. The aim of this study was to provide population pharmacokinetic analysis describing MDZ and its main metabolite 1-OH-midazolam (1-OH-MDZ) used during oral premedication in surgical paediatric patients. The influence of gender, age, and body weight on MDZ pharmacokinetics was also investigated.

Material and Methods The analyzed data set included 27 patients, aged 1 to 17 years, who received oral midazolam syrup before various surgical procedures. The 1-OH-MDZ concentration was approximated by a proportional relationship to MDZ concentration. Population nonlinear mixed-effect modeling was done using NONMEM 7.2. Non-parametric bootstrap and VPC were conducted to evaluate the adequacy of the model to describe the observations.

Results Midazolam pharmacokinetic model was developed to describe the time course of MDZ and 1-OH-MDZ concentrations. High inter-individual variability in volume of central compartment (93%) and clearance (60%) of MDZ w ere observed. The effect of body weight was accounted for by the allometric scaling. Significant differences in MDZ pharmacokinetics due to the age and gender were not found.

Conclusions The population MDZ pharmacokinetic model was successfully developed for paediatric patients. Age, gender do not explain inter-individual variation in the pharmacokinetics of MDZ. No effect of maturation was detected.

Downloads

Download data is not yet available.

Author Biography

Alicja Bartkowska-Śniatkowska, Poznan University of Medical Sciences, Department of Paediatric Anaesthesiology and Intensive Therapy

Deaprtment of Anaesthesiology and Intensive Therapy

References

Olkkola KT, Ahonen J. MDZ and Other Benzodiazepines in Modern Anesthetics. In: The Handbook of Experimental Pharmacology. Springer: Heidelberg, 2008;182:335–360.

Pacifici GM. Clinical pharmacology of MDZ in neonates and children: effect of disease – a review. Int J Ped. 2014;2014: 309342.

Blumer J. Clinical pharmacology of MDZ in infants and children. Clin Pharmacokinet 1988;35:37–47.

Anderson BJ, Larsson PA. Maturation model for MDZ clearance. Paediatr Anaesth. 2011;21: 302–308.

Jacqz-Aigrain E, Daoud P, Burtin P, Maherzi S, Beaufils F. Pharmacokinetics of MDZ during continuous infusion in critically ill neonates. Eur J Clin Pharmacol. 1992;42:329–332.

Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny JF, Betremieux P, et al. Population pharmacokinetics of MDZ in neonates. Clin Pharmacol Ther. 1994;56:615–625.

Hughes J, Gill AM, Mulhearn H, Powell E, Choonara I. Steady-state plasma concentrations of MDZ in critically ill infants and children. Ann Pharmacother. 1996;30:27–30.

Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47:231–243.

Anderson BJ, Allegaert K, Holford NHG. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–829.

Bienert A, Bartkowska-Sniatkowska A, Wiczling P, Rosada-Kurasińska J, Grześkowiak M, Zaba C, et al. Assessing circadian rhythms during prolonged MDZ infusion in the pediatric intensive care unit (PICU) children. Pharmacol Rep. 2013;65:107–121.

Holford N, Heo Y, Anderson B. A Pharmacokinetic Standard for Babies and Adults. J Pharm Sci. 2013;102:2941–2952.

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models AAPS J. 2011;13:143–151.

Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59:19–29.

De Gast-Bakker DA, van der Werff SD, Sibarani-Ponsen R, Swart EL, Plötz FB. Age is of influence on MDZ requirements in a paediatric intensive care unit. Acta Paediatr. 2007;96:414–417.

Maitre PO, Bührer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to MDZ. J Pharmacokinet Biopharm. 1991;19:377–384.

Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther. 2008;83:670–671.

Nahara MC, McMorrow J, Jones PR, Anglin D, Rosenberg R. Pharmacokinetics of MDZ in critically ill pediatric patients. Eur J Drug Metab Pharmacokinet. 2000;25:219–221.

Guo T, Mao GF, Xia DY, Su XY, Zhao LS. Pharmacokinetics of MDZ tablet in different Chinese ethnic groups. J Clin Pharm Ther. 2011;36:406–411.

de Wildt SN, de Hoog M, Vinks AA, van der Giesen E, van den Anker JN. Population pharmacokinetics and metabolism of MDZ in pediatric intensive care patients. Crit Care Med. 2003;31:1952–1958.

Wells TG, Ellis EN, Casteel HB. Pharmacokinetics of a single dose MDZ in children. Clin Pharmacol Ther. 1991;49:160.

Johnson TN, Rostami-Hodjegan A, Goddard JM, Tanner MS, Tucker GT. Contribution of MDZ and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth. 2002;89:428–437.

Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23:1110–1116.

Noda T, Todini T, Watanabe Y, Yamamoto S. Liver volume in children measured by computer thomography. Pediat Radiol. 1997;27:250–252.

Altamimi M, Sammons H, Choonara I. Inter-individual variation in MDZ clearance in children. Arch Dis Child. 2015;100:95–100.

Ince I, de Wildt SN, Peeters MY, Murry DJ, Tibboel D, Danhof M, et al. Critical illness is a major determinant of MDZ clearance in children aged 1 month to 17 years. Ther Drug Monit. 2012;34:381–389.

Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth. 1996;77:32–49.

Christie J, Markowsky SJ, Valdes C. Acute trauma alters morphine clearance. J Trauma. 1995;39:749–52.

Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85:434–438.